06 January 2023
HeiQ Plc
("HeiQ" or "the Company")
Director / PDMR Dealing
HeiQ Plc (LSE: HEIQ), a leading company in materials innovation and hygiene technologies, has been notified that on 5 January 2023, Carlo Centonze, Chief Executive Officer of the Company, purchased 261,171 ordinary shares in the Company ("Ordinary Shares") at a price of 28 pence per share.
Following the purchase, Mr. Centonze holds an interest in 14,448,317 Ordinary Shares, including 5,186,237 Ordinary Shares held by Cortegrande AG, a company wholly owned by Mr. Centonze. The total interest held by Mr. Centonze represents approximately 10.31 per cent. of the Company's issued ordinary share capital.
This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
| a)
| Name
| Mr. Carlo Centonze | ||||
| 2
| Reason for the notification
| |||||
| a)
| Position/status
| Chief Executive Officer | ||||
| b)
| Initial notification /Amendment
| Initial Notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
| a)
| Name
| HeiQ plc | ||||
| b)
| LEI
| 213800IGT65IMJDO4S03 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
| a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 30 pence each
GB00BN2CJ299
| ||||
| b)
| Nature of the transaction
| Purchase of Ordinary Shares | ||||
| c)
| Price(s) and volume(s)
|
| ||||
| d)
| Aggregated information
- Aggregated volume
- Price
| N/A
| ||||
| e)
| Date of the transaction
| 5 January 2023 | ||||
| f)
| Place of the transaction
| London Stock Exchange, Main Market | ||||
For further information, please contact:
| HeiQ Plc Carlo Centonze (CEO) | +41 56 250 68 50 |
| Cenkos Securities plc (Joint Broker) Stephen Keys / Callum Davidson | +44 (0) 207 397 8900 |
| SEC Newgate (Media Enquiries) Elisabeth Cowell / Axaule Shukanayeva / Molly Gretton | +44 (0) 20 3757 6882 |
About HeiQ
HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. HeiQ has strong IP which is at the forefront of global technology in the $10 billion antimicrobial fabrics market, $24 billion textile chemicals market, the $50 billion probiotics market and the $150 billion man-made fibers market. It has also moved into the medical device, healthcare and hygiene coatings markets, to help make hospitals and healthcare environments more hygienic. HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A.
HeiQ has created some of the most effective, durable and high-performance technologies in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands and it has a significant R&D pipeline containing over 50 projects. The Company has won multiple awards and gained a strong reputation for the ESG & sustainable downstream effect of its innovations. HeiQ is the only company to have won the Swiss Technology award twice. It has also won the Swiss Environmental award with an innovation that saves energy and water consumption during the textile manufacturing process.
Led by an experienced leadership team, HeiQ researches new solutions for partners, delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.